Frankfurt:4960

REPEAT - Irwin Naturals Closes Acquisition of Leading Kentucky Clinic adding $3 Million in Projected EBITDA, Company delivering on ambitious strategy to build largest global network of mental health clinics

Retrieved on:

Tuesday, February 21, 2023

Serenity, OTC, Acquisition, FRA, EBITDA, Patient, Ta' Braxia Cemetery, CSE, Psychiatry, Pharmaceutical industry

The acquisition, completed on February 16, 2023, marks two key milestones in Irwin’s Emergence clinics growth strategy in the mental health industry.

Key Points:

The acquisition, completed on February 16, 2023, marks two key milestones in Irwin’s Emergence clinics growth strategy in the mental health industry.
Klee Irwin, the CEO of Irwin Naturals, "With each clinic we bring under the Irwin Naturals Emergence umbrella, we establish our leadership in this innovative approach to mental healthcare.
The acquisition of Serenity Health by Irwin Naturals Emergence is a strategic move aimed at providing accessible and affordable mental healthcare to patients.
Braxia (“Braxia Scientific”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders (“Braxia LOI”).

Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific

Retrieved on:

Friday, January 27, 2023

LOS ANGELES, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), is pleased to announce it has entered into a non-binding amended and restated Letter of Intent (“LOI”) for a business combination with Braxia Scientific Corp. (“Braxia Scientific”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders.

Key Points:

LOS ANGELES, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), is pleased to announce it has entered into a non-binding amended and restated Letter of Intent (“LOI”) for a business combination with Braxia Scientific Corp. (“Braxia Scientific”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders.
The LOI sets forth the material terms and conditions upon which Irwin will acquire all of the issued and outstanding common shares (the “Braxia Shares”) of Braxia (the “Proposed Transaction”).
Dr. Roger McIntyre, CEO, Braxia Scientific commented, “With a proven track record of execution in the wellness sector spanning nearly three decades, Irwin has established a strong foothold in mental health.
Its growing network of US based clinics combined with its experienced team and access to capital, makes Irwin an excellent partner for Braxia.

Braxia Scientific Reports Q2 2023 Financial Results; Focused on Growing Clinic and Telemedicine Delivery of Novel Mental Health Treatments in North America

Retrieved on:

Tuesday, November 29, 2022

Our U.S. telemedicine platform, KetaMD, is providing access to safe, virtually guided at-home ketamine treatments in Florida where 2.9 million adults have a mental health condition ."

Key Points:

Our U.S. telemedicine platform, KetaMD, is providing access to safe, virtually guided at-home ketamine treatments in Florida where 2.9 million adults have a mental health condition ."
During the quarter, Braxia Health clinics continued to steadily grow its ketamine program referral network across 5 cities.
The new clinic commenced ramping operations, including adding specialized nursing, medical and psychiatry personnel late October and delivered initial treatments in November.
Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Braxia Scientific Announces Voting Results from the Annual General and Special Meeting of Shareholders

Retrieved on:

Tuesday, November 1, 2022

For more details on the matters covered at the annual meeting, please refer to the Company's management information circular available on SEDAR at www.sedar.com .Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.

Key Points:

For more details on the matters covered at the annual meeting, please refer to the Company's management information circular available on SEDAR at www.sedar.com .Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
Through its medical solutions, Braxia aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others.
Braxia seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform.

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle the Growing Mental Health Crisis and Shortage of Mental Health Care Providers

Retrieved on:

Tuesday, October 4, 2022

Post-traumatic stress disorder, OTC, National Alliance on Mental Illness, Anxiety, News, Tropical Storm Ian, Telehealth, Lists of diseases, Euro-Excellence Inc v Kraft Canada Inc, National Alliance, Psychiatry, National Helping Families in Mental Health Crisis Day, National Suicide Prevention Week, Psilocybin, CEO, Ketamine, Population, CSE, Multimedia, Disorder, COVID-19, Mental disorder, Risk, Awareness, Growth, CDSA, The Journal of Clinical Psychiatry, Clifford Whittingham Beers, Rapids, Quality of life, Controlled Drugs and Substances Act, Journal, Suicidal ideation, Patient, Person, Drug prohibition law, Diagnosis, Removal of cannabis from Schedule I of the Controlled Substances Act, Forward-looking statement, Intention, Mental health, Depression, Company, Mental Illness Awareness Week, Pharmaceutical industry, Medicine, Audit

KetaMD is committed to battling the growing mental health crisis and alleviating the growing shortage of mental health care providers in Florida and across America, both issues further exacerbated by the COVID-19 pandemic.

Key Points:

KetaMD is committed to battling the growing mental health crisis and alleviating the growing shortage of mental health care providers in Florida and across America, both issues further exacerbated by the COVID-19 pandemic.
Mental Health Crisis by the Numbers:
1 in 5 U.S. adults experience mental illness each year.
Over 6.3 million people in Florida live in a community that does not have enough mental health professionals.
Florida ranks 49th in the nation for access to mental health care, according to Mental Health America.

Braxia Scientific Announces Court Approval of Class Action Settlement in Canada

Retrieved on:

Saturday, September 17, 2022

TORONTO, Sept. 16, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) announced today that the Supreme Court of British Columbia has approved a settlement of a class action lawsuit that was filed in May 2021 against Braxia Scientific, its CEO, certain of its former officers, a shareholder, and underwriters (the "Canadian Settlement").

Key Points:

TORONTO, Sept. 16, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960) announced today that the Supreme Court of British Columbia has approved a settlement of a class action lawsuit that was filed in May 2021 against Braxia Scientific, its CEO, certain of its former officers, a shareholder, and underwriters (the "Canadian Settlement").
The court approval of an agreement in principle (the "US Settlement") to settle claims alleged in a securities class action (the "US Class Action") against the Company and certain of its former officers filed in the United States District Court for the Central District of California in April, 2021, remains pending.
The US Settlement contemplates a cash payment by the Company of USD $1 million to settle the US Class Action.
After available insurance, and assuming the court approval of the US Settlement is obtained, the total cost to the Company to settle both class actions will be approximately CDN $1.36million.

Braxia Scientific Launches KetaMD in Florida; First Patients Complete Initial Virtual Ketamine Treatments At-Home

Retrieved on:

Monday, September 12, 2022

KetaMD onboarded new patients and completed initial ketamine treatments.

Key Points:

KetaMD onboarded new patients and completed initial ketamine treatments.
Dr. Roger McIntyre commented, "We are incredibly proud to have treated our first patients in the U.S. through our KetaMD platform.
KetaMD is a HIPAA-compliant telemedicine platform providing affordable and potentially life-changing at-home medical ketamine treatments.
Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine and psilocybin treatments for people with depression and related disorders.

Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022

Retrieved on:

Friday, September 9, 2022

TORONTO, Sept. 9, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Annual Global Investment Conference being held in New York, September 12-14, 2022.

Key Points:

TORONTO, Sept. 9, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Annual Global Investment Conference being held in New York, September 12-14, 2022.
Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright.
Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.
Through its medical solutions, Braxia aims to reduce the illness burden of brain-based disorders, such as major depressive disorder among others.

Braxia Scientific Reports Q1 2023 Financial Results; Launches KetaMD in U.S. Increasing Treatment Access for Mental Health Patients

Retrieved on:

Monday, August 29, 2022

Braxia Scientific completed the acquisition and launch of KetaMD, a new end-to-end telemedicine platform, that utilizes leading technology, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions.

Key Points:

Braxia Scientific completed the acquisition and launch of KetaMD, a new end-to-end telemedicine platform, that utilizes leading technology, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions.
Treatments are medically supervised, guided virtually by registered nurses with mental health expertise, and backed by the world's leading psychiatrists and researchers in depression.
KetaMD is currently available in theState of Floridawith a roll-out to other key states to begin in 2022.
Braxia Health received multiple approvals from Health Canada to the Special Access Program ("SAP") to provide psilocybin-assisted psychotherapy for patients with Major Depressive Disorder outside of clinical trials.

Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with plans to expand across the U.S.

Retrieved on:

Wednesday, August 3, 2022

KetaMD is a U.S. based, privately-held, innovative telemedicine company, with a mission to address mental health challenges via access to technology-facilitated ketamine-based treatments.

Key Points:

KetaMD is a U.S. based, privately-held, innovative telemedicine company, with a mission to address mental health challenges via access to technology-facilitated ketamine-based treatments.
KetaMD's end-to-end telemedicine platform, utilizing leading technology, provides access to safe, affordable, and potentially life-changing at-home ketamine treatments for people suffering from depression and related mental health conditions.
I'm delighted the KetaMD leadership will be bringing their immeasurable talents as key leaders in the organization and as Braxia shareholders."
KetaMD is currently available in the State of Florida but a roll-out to other key states is planned in 2022.